These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Properties of pathogen-inactivated plasma components. Prowse C Transfus Med Rev; 2009 Apr; 23(2):124-33. PubMed ID: 19304113 [TBL] [Abstract][Full Text] [Related]
48. UV-C treatment of protein solutions. Macleod AJ; Li Q; Bienek C; Foster PR Biologicals; 2007 Oct; 35(4):373. PubMed ID: 17254799 [No Abstract] [Full Text] [Related]
49. Virus inactivation during the freeze-drying processes as used for the manufacture of plasma-derived medicinal products. Unger U; Poelsler G; Modrof J; Kreil TR Transfusion; 2009 Sep; 49(9):1924-30. PubMed ID: 19453977 [TBL] [Abstract][Full Text] [Related]
50. Chlorine inactivation of coliphage MS2 on strawberries by industrial-scale water washing units. Casteel MJ; Schmidt CE; Sobsey MD J Water Health; 2009 Jun; 7(2):244-50. PubMed ID: 19240350 [TBL] [Abstract][Full Text] [Related]
52. Statistical methods to the control of the production of blood components: principles and control charts for variables. Pereira P; Seghatchian J; Caldeira B; Xavier S; de Sousa G Transfus Apher Sci; 2018 Feb; 57(1):132-142. PubMed ID: 29526479 [TBL] [Abstract][Full Text] [Related]
53. Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007;92:846-9. Gröner A Haematologica; 2008 Feb; 93(2):e24-6; author reply e27. PubMed ID: 18245642 [No Abstract] [Full Text] [Related]
54. Universal leukoreduction of cellular blood components in 2001? Yes. Sweeney JD Am J Clin Pathol; 2001 May; 115(5):666-73. PubMed ID: 11345829 [No Abstract] [Full Text] [Related]
55. Universal leukoreduction of cellular blood components in 2001? Garcia A; Veillon DM; McCaskill D Am J Clin Pathol; 2001 Nov; 116(5):778-80. PubMed ID: 11710697 [No Abstract] [Full Text] [Related]
56. 2012 and beyond. Roberts DJ Transfus Med; 2012 Feb; 22(1):1-2. PubMed ID: 22332646 [No Abstract] [Full Text] [Related]
57. Wide variation in effectiveness of laboratory disinfectants against bacteriophages. Halfhide DE; Gannon BW; Hayes CM; Roe JM Lett Appl Microbiol; 2008 Dec; 47(6):608-12. PubMed ID: 19120934 [TBL] [Abstract][Full Text] [Related]
58. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview. Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519 [TBL] [Abstract][Full Text] [Related]
59. Use of fresh-frozen plasma at Royal Darwin Hospital: a retrospective audit. Moylan S; Szabo F; Scott H; Kwok G Intern Med J; 2008 Sep; 38(9):686-91. PubMed ID: 19143886 [TBL] [Abstract][Full Text] [Related]
60. Is there a role for apheresis in gastrointestinal disorders? Hibi T; Sakuraba A Nat Clin Pract Gastroenterol Hepatol; 2005 May; 2(5):200-1. PubMed ID: 16265186 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]